Ziglim-M1 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 1 mg and Metformin 500 mg, designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. The prolonged-release formulation of Ziglim-M1 ensures a steady release of active ingredients, promoting sustained therapeutic effects and improved patient compliance. This combination is indicated for patients inadequately controlled on diet and exercise alone or those requiring dual therapy to achieve optimal glycemic targets. Ziglim-M1 should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular monitoring of blood glucose levels. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or a history of lactic acidosis. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, as well as hypoglycemia due to Glimepiride. Regular monitoring of blood glucose and periodic assessment of renal function are recommended during therapy. Ziglim-M1 Tablet PR should be prescribed and used under medical supervision to ensure safety and efficacy.